Stocks · Pharmaceuticals

Pfizer Inc. (PFE)

$29.75

−0.13% last session

Market value

$169.8bn

P/E ratio

39.2

Dividend yield

5.38%

52-week range

$24–$30

What Pfizer Inc. does

is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit.

Pharmaceuticals · based in the US · listed since 1944Biggest source of revenue: Product (83%) · breakdownCompany website ↗

Report card

tap a grade for the details

DGrowthBarely growing

Sales growth, last 12 months−0.2% · 29/100

Sales growth a year, 5 years8.5% · 64/100

Earnings per share growth a year, 5 years−3.5% · 21/100

DProfitabilityThin profits

Net profit margin6.8% · 52/100

Return on equity5% · 35/100

BFinancial strengthStrong

Current ratio (short-term assets ÷ debts)1.27 · 73/100

DValuationLooks expensive

P/E against its own 10-year history91th percentile · 9/100

Free cash flow yield6.5% · 89/100

Our base-case value vs price−26% · 25/100

AMomentumStrong uptrend

Share price, last 12 months21.7% · 78/100

Share price, last 3 months22.4% · 100/100

Price

+20.1% over 1Y

27 Oct 2026$29.75

Daily closing prices. Source: Twelve Data.

Bull vs bear

The numbers lean bearish (3 vs 11)

The bull case

Shareholder-friendly management●●○

Passes 5 of 6 capital-allocation checks.

Reliable dividend grower●○○

Raised its dividend 10 years in a row.

The bear case

Expensive against its own history●●●

P/E 39.4 vs a 10-year median of 18.8 (range 9–78).

Cyclical revenue●●○

Revenue fell in 4 of the last 10 years: results can swing with the economy.

Growth is slowing●●○

Revenue growth over the last 12 months (-0%) is well below its 5-year average (8%).

Our cash-flow model says it's pricey●●○

Base case 26% below today's price.

Above analysts' average target●○○

The price is 2% above where analysts on average expect it in a year.

Recoveries can take years●○○

Took 74 months to recover after the 1973 fall.

Can you answer every bear point? Put your answers in your thesis under risks.

See the full picture on Pfizer Inc.

Ten years of results, revenue by product and region, a management scorecard, bear/base/bull valuations, analyst targets, every SEC filing explained, and a thesis that checks itself after each report. Free.

Create a free account Already a member? Open PFE

Pfizer Inc. (PFE)

Report card iLearn

Price

Bull vs bear iLearn

See the full picture on Pfizer Inc.

Bull vs bear iLearn

Report card iLearn

Report card

Bull vs bear

Bull vs bear

Report card